Related Experiment Video
Updated: Jan 21, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Metformin and ovarian cancer survival: is there a rational warrant for belief?
1Division of Pediatrics and Neonatology, Moscati Hospital, Via A. Gramsci, 81031, Aversa, Italy. raffaellamormile@libero.it.
Abstract:
Metformin (MF) represents the first-line drug used to treat type 2 diabetes. Recently, MF has also been reported to be a potential and promising anti-cancer agent for some gynecological cancers' prevention. MF, as an anti-tumorigenic factor, may reduce the chance of developing ovarian cancer by targeting IL-6. By acting on IL-6 expression, metformin might have a positive impact on the main molecular pathways strictly connected with pathogenesis and biological features of ovarian cancer. Further investigation is warranted to better define the use of MF as a possible treatment option in the fight against ovarian cancer.
Related Concept Videos
Cancer Survival Analysis
Rational Emotive Behavior Therapy
Survival Tree
Building a Survival Tree
Constructing a...
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...
Comparing the Survival Analysis of Two or More Groups

